The Consumers Union of Russia has proposed that e-cigarettes be classified as prescription products and sold exclusively in pharmacies, VM.RU reported on November 1. The proposal was submitted to Russian Prime Minister Mikhail Mishustin.
The alliance stated that e-cigarettes and related devices should be treated like medications, requiring a doctor’s prescription for purchase. Currently, around 4.5 million people in Russia use e-cigarettes to satisfy nicotine cravings.
Data from Russia’s National Statistics Bureau shows that the smoking rate dropped from 41% in 2009 to 30% in 2023. However, addiction issues remain, particularly concerning e-cigarettes.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
